{"id":304,"date":"2019-11-20T19:32:56","date_gmt":"2019-11-20T18:32:56","guid":{"rendered":"https:\/\/porphyria.network\/IPPN\/?p=304"},"modified":"2021-07-20T08:26:44","modified_gmt":"2021-07-20T06:26:44","slug":"the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria","status":"publish","type":"post","link":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/","title":{"rendered":"The FDA approves givosiran for AHP!"},"content":{"rendered":"\n<p>These are exciting times for the porphyria patient community: After the recent FDA approval of afamelanotide to treat patients with EPP, today, the US agency approved givosiran for the treatment of adult patients with acute hepatic porphyria (AHP). Prior to today&#8217;s approval, therapeutic options available to patients with AHP were only able to partially manage the recurrent acute and painful attacks that patients with AHP can suffer. With givosiran, patients now have a new option, which helps significantly reduce the number of attacks that require urgent medical interventions. The IPPN is delighted by today&#8217;s news and looks forward to givosiran being made broadly available to patients in need and to further approvals in more parts of the world.<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-inherited-rare-disease\">FDA News Release on Givosiran Approval<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>These are exciting times for the porphyria patient community: After the recent FDA approval of afamelanotide to treat patients with EPP, today, the US agency approved givosiran for the treatment of adult patients with acute hepatic porphyria (AHP). Prior to today&#8217;s approval, therapeutic options available to patients with AHP were only able to partially manage&hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[31],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The FDA approves givosiran for AHP! - International Porphyria Patient Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The FDA approves givosiran for AHP! - International Porphyria Patient Network\" \/>\n<meta property=\"og:description\" content=\"These are exciting times for the porphyria patient community: After the recent FDA approval of afamelanotide to treat patients with EPP, today, the US agency approved givosiran for the treatment of adult patients with acute hepatic porphyria (AHP). Prior to today&#8217;s approval, therapeutic options available to patients with AHP were only able to partially manage&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/\" \/>\n<meta property=\"og:site_name\" content=\"International Porphyria Patient Network\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-20T18:32:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-20T06:26:44+00:00\" \/>\n<meta name=\"author\" content=\"Editorial Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Editorial Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/\"},\"author\":{\"name\":\"Editorial Team\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\"},\"headline\":\"The FDA approves givosiran for AHP!\",\"datePublished\":\"2019-11-20T18:32:56+00:00\",\"dateModified\":\"2021-07-20T06:26:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/\"},\"wordCount\":130,\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"articleSection\":[\"English\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/\",\"name\":\"The FDA approves givosiran for AHP! - International Porphyria Patient Network\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\"},\"datePublished\":\"2019-11-20T18:32:56+00:00\",\"dateModified\":\"2021-07-20T06:26:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/porphyria.network\/IPPN\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The FDA approves givosiran for AHP!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"name\":\"International Porphyria Patient Network\",\"description\":\"Welcome to the International Porphyria Patient Network\",\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\",\"name\":\"International Porphyria Patient Network\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"contentUrl\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"width\":671,\"height\":630,\"caption\":\"International Porphyria Patient Network\"},\"image\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\",\"name\":\"Editorial Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"caption\":\"Editorial Team\"},\"url\":\"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The FDA approves givosiran for AHP! - International Porphyria Patient Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/","og_locale":"en_US","og_type":"article","og_title":"The FDA approves givosiran for AHP! - International Porphyria Patient Network","og_description":"These are exciting times for the porphyria patient community: After the recent FDA approval of afamelanotide to treat patients with EPP, today, the US agency approved givosiran for the treatment of adult patients with acute hepatic porphyria (AHP). Prior to today&#8217;s approval, therapeutic options available to patients with AHP were only able to partially manage&hellip;","og_url":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/","og_site_name":"International Porphyria Patient Network","article_published_time":"2019-11-20T18:32:56+00:00","article_modified_time":"2021-07-20T06:26:44+00:00","author":"Editorial Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Editorial Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/#article","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/"},"author":{"name":"Editorial Team","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765"},"headline":"The FDA approves givosiran for AHP!","datePublished":"2019-11-20T18:32:56+00:00","dateModified":"2021-07-20T06:26:44+00:00","mainEntityOfPage":{"@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/"},"wordCount":130,"publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"articleSection":["English"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/","url":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/","name":"The FDA approves givosiran for AHP! - International Porphyria Patient Network","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/#website"},"datePublished":"2019-11-20T18:32:56+00:00","dateModified":"2021-07-20T06:26:44+00:00","breadcrumb":{"@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/the-fda-approves-givosiran-for-the-treatment-of-adult-patients-with-acute-hepatic-porphyria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/porphyria.network\/IPPN\/"},{"@type":"ListItem","position":2,"name":"The FDA approves givosiran for AHP!"}]},{"@type":"WebSite","@id":"https:\/\/porphyria.network\/IPPN\/#website","url":"https:\/\/porphyria.network\/IPPN\/","name":"International Porphyria Patient Network","description":"Welcome to the International Porphyria Patient Network","publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/porphyria.network\/IPPN\/#organization","name":"International Porphyria Patient Network","url":"https:\/\/porphyria.network\/IPPN\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/","url":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","contentUrl":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","width":671,"height":630,"caption":"International Porphyria Patient Network"},"image":{"@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765","name":"Editorial Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","caption":"Editorial Team"},"url":"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/"}]}},"_links":{"self":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/304"}],"collection":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/comments?post=304"}],"version-history":[{"count":5,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/304\/revisions"}],"predecessor-version":[{"id":311,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/304\/revisions\/311"}],"wp:attachment":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/media?parent=304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/categories?post=304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/tags?post=304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}